Zusammenfassung
Die Effektivität der Chemotherapie eines Tumors ist abhängig von dessen Wachstumsfraktion, d.h. dem im aktiven Zellzyklus befindlichen Anteil der Tumorzellen. Dies gilt insbesondere für zellzyklus-phasenspezifische Zytostatika wie z. B. die Antimetaboliten, die nur in der S-Phase wirksam werden können und die Spindelgifte in der M-Phase. Für diese Zytostatika besteht also eine temporäre Resistenz für den Anteil Tumorzellen, die sich derzeit nicht in der empfindlichen Phase befinden, die jedoch zu einem anderen Zeitpunkt in diese Zyklusphase rekrutiert werden können. Bei einigen Tumoren mit hoher Wachstumsrate ist daher heute die systemische Chemotherapie in kurativer Absicht einsetzbar, wie bei malignen Lymphomen und Leukämien, aber auch bei einigen soliden Tumoren. Da in diesen Fällen eine anderweitige Heilungschance nicht besteht, können schwerwiegende akute oder auch Langzeitnebenwirkungen in Kauf genommen werden. Die palliative Therapie hingegen zielt lediglich auf eine Besserung der Symptome ohne Heilungsaussichten der Erkrankung ab. Stark nebenwirkungsreiche Therapieschemata sind daher hierbei nicht gerechtfertigt. Zytostatika können nicht selektiv auf Tumorzellen wirken, da keine grundsätzlichen biochemischen Unterschiede zwischen Tumorzellen und normalen Zellen bestehen. Es ist
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Oki T, Takeuchi T, Oka S et al. (1980) Current status of Japanese studies with the new anthracycline antibiotic Aclacinomycin A. Recent Results Cancer Res 74: 207–216
Skovsgaard T (1987) Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin. Eur J Haematol (Suppl) 38: 7
Mitrou PS (1983) Therapieergebnisse mit Aclacinomycin A bei rezidivierenden akuten Leukämien. Onkologie 6: 192–194
Tattersall NHM, Sodergren JE, Segupta IK et al. (1975) Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 17: 107–108
Pigram WJ, Fuller W, Amilton LDH (1972) Stereochemistry of intercalation: Interaction of daunorubicin with DNA. Nature 235: 17–9
Liu LF. Rowe TC, Young L et al. (1983) Cleavage of DNA by mammalian DNA topoisomerase-II. J Bio Chem 258: 15365–15370
Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353–1356
Benjamin RS (1974) Pharmacokinetics of adriamycin in patients with sarcomas. Cancer Chemother Res 58: 271–273
Lipton A, Sanrten RJ (1974) Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer. Cancer 33: 503–512
Thompson TA, Vermeulen JO. Wagner WE et al. (1981) Aminoglutethimide bioavailability, pharmacokinetics and binding to blood constituents. J Pharmaceut Sci 70:1040–1043
Bruning PF, Bonfrer JGM (1983) Aminoglutethimide and oral anticoagulant therapy. Lancet I: 582
Rowe TG, Chen GL, Hsiang YH et al. (1986) DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase-II. Cancer Res 46: 2021–2026
Hall SW, Friedman SS, Legha RS et al. (1983) Human pharmacokinetics of a new acridine derivate. Cancer Res 43: 3422
Wong A: Hunag CH, Crooke ST (1984) Studies on the fluorescence–labelling of human red blood cell membrane ghosts with m-AMSA. Proc Am Assoc Cancer Res 25: 49
Yu DTY (1974) Lymphocyte characteristics in rheumatic patients and the effect of azathioprine therapy. Arthritis Rheum 17: 37–42
Hersh EM, Wong VC, Freireich EJ (1966) Inhibition of the local inflammatory response in man by antimetabolites. Blood 27: 38–44
Wu JC, Stubbe J, Kozarich JW (1985) Mechanism of bleomycin. Biochemistry 24: 7569–7573
Alberts DS, Chen HSG, Liu R et al. (1978) Bleomycin pharmacokinetics in man. 1. Intravenous administration. Cancer Chemother Pharmacol 1: 177–181
Ostrowski MJ (1989) Intracavitary therapy with bleomycin for the treatment of malignant pleural effusions. J Surg Oncol Suppl 1: 7–13
Hehlmann R, Heimpel H, Hasford J et al. (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. Blood 82: 398–407
Ehrsson H, Hassan M, Ehrnebo M et al. (1983) Busulfan kinetics. Clin Pharmacol, Ther 34: 86–90
Pode D, Pireberg S, Steiner D (1983) Busulfan-induced hemorrhagic cystitis. J Urol 130: 347
von Hoff DD (1987) Whither carbaplatin? A replacement for or an alternative to cisplatin. J Clin Oncol 5: 169–170
Muggia FM (1989) Overview of carboplatin: replacement, complementing and extending the therapeutic horizons of cisplatin. Semin Oncol 15: 7–13
De Vita VT (1965) Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 25: 1876–1881
Wassermann TH, Slavik M. Carter SK (1975) Clinical comparison of the nitrosoureas. Cancer 36: 1258–1268
Weinstein AS, Diener-West SM, Nelson DF et al. (1986) Pulmonary toxicity of carmustine in patients treated for malignant gliomas. Cancer Treat Rep 70: 943–946
Byrne TN, Moseley TAE, Finer MA (1981) Myoclonic seizures following chlorambucil overdose. Ann Neurol 9: 191–193
Lane SD, Besa EC, Justh G et al. (1981) Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocytic leukemia. Cancer 47: 32–36
Ducore JM, Erickson LC, Zwelling LA et al. (1982) Comparative studies of DNA-cross linking and cytotoxicity in Burkitt lymphoma cell lines treated with cisdiamine-dichloro-platinum ( II) and L-phenylalanine mustard. Cancer Res 4: 897
Drewinko B, Patchen M, Yang LY et al. (1981) Differential killing efficacy of twenty antitumor drugs on proliferating and non-proliferating human tumor cells. Cancer Res 41: 2328–2333
Brock N (1971) Activation of cyclophosphamide in man and animal. Cancer 6: 1512–1529
Sladek NIE, Powers JF, Grage GM (1984) Half-life of oxazaphosphorines in biological fluids. Drug Metabol Dispos 12: 553–559
Juma FD (1984) Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol 26: 591–593
Manohoran A (1984) Carcinoma of the urinary bladder in patients receiving cyclophosphamide. Aust NZ J Med 14: 507–512
Steinherz JJ, Steinherz PG (1985) Cyclophosphamide cardiotoxicity. Cancer Bull 37: 231–234
Alvarado CS. Boat TF, Newman AJ (1978) Late onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide. J Pediatr 92: 443–446
Neumann F, Töpert M (1986) Pharmacology of antiandrogens. J Steroid Biochem 25: 885–895
Brown TR, Rothwell SW, Sulktan C et al. (1981) Inhibition of androgen binding in human foreskin fibroblasts by antiandrogens. Steroids 37: 635–648
Tvetter KJ, Otnes B, Hamnestad R (1978) Treatment of prostate cancer with cyproteroneacetate. Scand J Urol Nephrol 12: 115
Ho DHW, Frei E (1971) Clinical pharmacology of 1-ß-D-arabinofuranosylcytosine. Clin Pharmacol Ther 12: 944 - 954
Ritch PS (1983) Ocular toxicity from high dose cytosine arabinoside. Cancer 51: 430–432
Lazarus HM (1981) Central nervous system toxicity of high dose systemic cytosine arabinoside. Cancer 48: 2577
Bono VH (1976) Studies on the mechanism of DTIC. Cancer Treat Rep 60: 141–148
Breithaupt H, Damann A, Aigner K (1982) Pharmacokinetics of DTIC and its metabolite 5-aminoimidazole-4-carboxamide, following different dose schedules. Cancer Chemother Pharmacol 9: 103–109
Feaux de Lacroix W, Runne U, Hauk H et al. (1983) Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment. Cancer Treat Rep 67: 779–782
Tewey KM, Chen GL, Nelson EM et al. (1984) Intercalation antitumor drugs interfere with the breakage-reunion reaction mammalian DNA topoisomerase II. J Biol Chem 259: 9182–9187
Büchner T, Hiddemann W, Königsmann M et al. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor alter chemotherapy in patients with acute myeloid leukemia at higher age or relapse. Blood 78: 1190–1197
Hoelzer D (1991) High-dose chemotherapy in adult acute lymphoblastic leukemia. Semin Hematol 28 (Suppl 4): 84
Jain KK, Caspers ES, Geller NL (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3: 818
Torti FM, Bristow MM, Lum BL (1986) Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46: 3722
Hauser AR, Marryman R (1984) Estramustin phosphate sodium. Drug Intell Clin Pharmacol 18: 368–374
Haim N, Roman J, Nemec J et al. (1986) Peroxidative free radical formation and o-demethylation of etoposide (VP-16) and teniposide (VM-26), Biochem Biophys Res Commun 135: 215–220
Allen LM, Creaven PJ (1975) Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur J Cancer 11: 697–707
Radice PA, Bunn PA, Ihde DC (1979) therapeutic trials with VP 162131 and VM 26: active agents in small cell lung cancer, non Hodgkin’s lymphomas and other malignancies. Cancer Treat Rep 63: 1231–1239
Dwyer PJ, Leyland-Jones B, Alonso MT (1985) Drug therapy: Etoposide (VP 16-213): Current status of an active anticancer drug. N Engl J Med 312: 692–700
Redman JR, Cabanillas F, Velasquez WS et al. (1992) Phase 11 Trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 10: 790–794
Chun HG, Leyland-Jones BR, Cary KSM et al. (1986) Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70: 1225–1288
Heidelberger C, Chandhari NK, Daunenberg P et al. (1957) Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 179: 663–666
Lokich JJ, Ahlgren JD, Guilo JJ et al. (1989) A prospective randomized comparison of continuous infusion. Fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program Study. J Clin Oncol 4: 425–432
Poon M, O’Connel MJ, Moertel CG (1989) Biochemical modulation of fluorouracil: Evidence of significant improvement of survical and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 10: 1407–1418
Knuth HA, Hano R, Nieschlag E (1984) Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab 59: 963–969
Geller J, Albert J, Vik A (1988) Advantages of total androgen blockade in the treatment of advanced prostatic cancer. Semin Oncol 15 (Suppl. 1): 53–61
Lord BI, Bronchud MH, Owens S et al. (1989) The kinetic of human granulopoiesis following treatment with colony-stimulating factor in vivo. Proc Natl Acad Sci USA 86: 9499–9503
Welte K, Zeidler C, Reiter A et al. (1990) Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 75: 1056–1063
Layton JE, Hockman H, Sheridan WP et al. (1989) Evidence of a novel in vivo control mechanism of granulopoesis: mature cell-related control of a regular growth factor. Blood 74: 1303–1307
Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 327: 28–35
Ohno R, Tomonaga M, Kobayashi HM et al. (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Eng J Med 323: 871–877
Heinemann V, Schulz L, Issels RD, Plunkett W (1995) Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Sem Oncol 22: 11–19
Büchner T, Hiddemann W, Königsmann M et al. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or relapse. Blood 78: 1190–1197
Cebon J, Dempsey P, Fox R et al. (1988) Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay. Blood 72: 1340–1347
Berman E, Heller G, Gantorsa J et al. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77: 1666–1674
Reid JM, Pendergrass W, Krailo MD et al. (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a children’s cancer study group report. Cancer Res 50: 6525–6528
Allen LM (1976) Studies on the human pharmacokinetics of ifosfamide (NSC-109724). Cancer Treat Rep 60: 451–458
Andriole GL, Sandlund JT, Miser JS et al. (1987) The efficacy of MESNA (2-mercaptoethane-sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphospharine chemotherapy. J Clin Oncol 5: 799–803
Wheeler BM (1986) Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4: 28–34
Gutterman JU, Fine S, Quesida JR et al. (1982) Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance and biologic effects in cancer patients. Arm Intern Med 96: 549–556
von Wussow P, Freund M, Block B et al. (1987) Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet ii: 635636
von Wussow P, Jakschies O, Freund M et al. (1991) Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Brit J Haematol 78: 210–216
Rothenberg ML (1998) Topoisomerase I inhibitors: Review and update. Ann Oncol 8: 837–855
Ohnuma T, Holland JF, Meyer P (1972) Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer 30: 376–381
Homans AC, Rybah ME, Baglini RL et al. (1987) Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol 5: 811–817
Capizzi R (1975) Improvement in the therapeutic index of L-asparaginase by methotrexate. Cancer Chemother Rep 6: 37–41
Waxman Jh, Wass JAH, Henry HN (1983) Treatment with gonadotropin releasing hormone analogue in advanced prostatic cancer. Brit Med J 286: 1309–1312
Sandow J, Clayton RN (1983) The disposition, metabolism, kinetics and receptor binding properties of LHRH and its analogues. Prog Horm Biochem Pharmacol 2: 63–106
Smith KH (1988) Interleukin-2: Inception, impact and implications. Science 240: 1169–1175
Whittington R, Faulds D (1993) Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46: 446–514
Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137: 1735–1742
Sponzo RW (1973) Physiologic disposition of 1-(2-chloroethyl-)-3-(4methyl cyclohexyl)-1-nitrosourea (MeCCNU) in man. Cancer 31: 11541159
Cordonnier C, Vernant JP, Mital P et al. (1983) Pulmonary fibrosis subsequent to high dosis of CCNU for OML. Cancer 51: 1814–1818
Zeltzer PM, Feig SA (1979) Theophylline-induced lomustine toxicity. Lancet 2: 960–961
Alberts DS, Chen HS, Benz D et al. (1981) Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Brit J Cancer 43: 330–335
Perry MC (1982) Hepatotoxicity of chemotherapeutic agents. Semin Oncol 9: 65–74
Sauer H, Schalhorn A (1980) Rationale Grundlagen und Praxis des Citrovorumfaktor ( Leukovorin)-Schutzes nach hochdosierter Methotrexattherapie, Onkologie 3: 84–91
Jolivet J, Cowar KH, Curt L et al. (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094–1114
Kotz R, Leber H, Ramach W et al. (1977) Erfahrungen mit der Durchführung der hochdosierten Methotrexatbehandlung beim Osteosarkom. Wien Klin Wochenschr 89: 474–479
Evans WE, Pratt CB (1978) Effect of pleural effusion an high-dose methotrexate kinetics. Clin Pharmacol Ther 23: 68–72
Überall F, Oberhuber H, Maly K et al. (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res 51: 807–812
Gaafar R, Hamza MR, Gad el Mawla N (1992) Hexadecylphosphocholine in the topical treatment of skin metastasized breast cancer. J Egypt Nat Cancer Inst 5: 585–594
Traganos F (1983) Dihydroxyanthraquinone and related bis (substituted) aminoanthraquinones: a novel class of antitumor agents. Pharmacol Ther 22: 199–214
Musch E, Paar WD, Hoffmann B et al. (1989) Intrapleurale Instillation von Mitoxantron zur Palliativ-Therapie maligner Pleuraergüsse. Tumor Diagn Ther 10: 1–8
Kaufmann M, Schmid H, Kubli F (1988) Intraperitoneale MitoxantronApplikalion beim progredienten Ovarialkarzinom mit Aszitesbildung. In: Seeber S, Aigner KR, Enghofer E (Hrsg) Die lokoregionale Tumortherapie. de Gruyter, Berlin, S 61–70
Ehninger G, Weible KH, Heidemann E et al. (1984) Mitoxantrone in combination with cyclophsophamide in patients with advanced breast cancer. Cancer Treat Rep 68: 1283–1284
Rowinsky EK, Onetto N, Cantetta RM et al. (1992) Taxol: the first of the taxanes, an important new class o17 antitumor agents Semin On-col 19: 642–662
Schalhorn B (1993) Paclitaxel (Taxol) - ein Zytostatikum mit neuartigem Wirkmechanismus. Med Klin 88 (Suppl. 11): 4–15
Argawal RP (1982) Inhibitors of adenosine deaminase. Pharmacol Ther 17: 399–429
Hoffmann W, Seeber S (1991) Stellenwert von Prednimustin in der Behandlung fortgeschrittener Mammacarcinome und maligner Lymphome höher Stadien. Tumordiag Ther 12: 65–70
Spivack BB (1974) Procarbazine. Ann Intern Med 81: 795–800
Andersen E, Videbaek A (1980) Procarbazine-induced skin reactions in Hodgkin’s disease and other malignant lymphomas. Scand J Haematol 24: 149–151
Edward DT, Chamoess GC, McGuire WL (1979) Estrogene and progesterone receptor proteins in breast cancer. Biochem Biophys Acta 560: 457–459
Mouridsen H, Palskof T, Patterson J et al. (1978) Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131–138
Allen LM, Creaven PJ (1975) Comparison of human pharmacokinetics of VM-26 and VP-1 6, two antineoplastic epipodophyllotoxin glycopyranoside derivatives. Eur J Cancer 11: 697–707
von Pawel J (1997) Topotecan: Potent cytostatic action by selective topoisomerase I inhibition. Onkologie 20: 380–386
Cole DE, Blaney SM, Balis M (1995) Topotecan in physiologic fluids: Depot of active drugs in red blood cells. Proc Am Assoc Cancer Res 36: 363–366
Owelien RJ, Root MA, Hains FO (1977) Pharmacokinetics of vindesine and vincristine in humans. Cancer Res 37: 2603–2607
Femoleau P, Degado FM, Delozier T (1993) Phase-II-trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245–1252
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Zurborn, KH. (2000). Antineoplastische Therapie. In: Frölich, J.C., Kirch, W. (eds) Praktische Arzneitherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09398-6_19
Download citation
DOI: https://doi.org/10.1007/978-3-662-09398-6_19
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-66071-2
Online ISBN: 978-3-662-09398-6
eBook Packages: Springer Book Archive